open access

Vol 68, No 4 (2018)
Review paper
Published online: 2019-01-16
Get Citation

The multidirectional role of osteopontin in cancer

Michał Piotr Budzik, Anna Maria Badowska-Kozakiewicz
DOI: 10.5603/NJO.2018.0029
·
Nowotwory. Journal of Oncology 2018;68(4):176-183.

open access

Vol 68, No 4 (2018)
Review article
Published online: 2019-01-16

Abstract

Osteopontin (OPN) was described for the first time as a potential marker of neoplastic transformation by Senger et al. in 1979. Studies suggesting an important role of OPN in oncology, allergology, nephrology and cardiology have been published for many years. However, the largest number of articles pertains to the role of OPN in neoplastic transformation and will surely facilitate future determination of OPN levels in blood or cancer tissues with the pur­pose of disease diagnosing, staging, prognosing metastases and monitoring the treatment effectiveness. Numerous studies showed that high OPN expression levels accompany metastases formation; the protein was also confirmed to be involved in stimulation of cell proliferation and formation of new blood vessels, i.e. angiogenesis.

OPN was also shown to be capable of binding the CD-44 receptors, which facilitates migration and invasion of cancer cells into the blood vessels. Correlation was also demonstrated between OPN expression and the time to disease recurrence and overall survival in patients with breast cancer, gastric cancer, hepatocellular cancer, hormone-depen­dent prostate cancer, kidney cancer and endometrial cancer.

The exact mechanism responsible for OPN’s role in neoplastic transformation remains unclear and numerous research studies are conducted in this area.

Abstract

Osteopontin (OPN) was described for the first time as a potential marker of neoplastic transformation by Senger et al. in 1979. Studies suggesting an important role of OPN in oncology, allergology, nephrology and cardiology have been published for many years. However, the largest number of articles pertains to the role of OPN in neoplastic transformation and will surely facilitate future determination of OPN levels in blood or cancer tissues with the pur­pose of disease diagnosing, staging, prognosing metastases and monitoring the treatment effectiveness. Numerous studies showed that high OPN expression levels accompany metastases formation; the protein was also confirmed to be involved in stimulation of cell proliferation and formation of new blood vessels, i.e. angiogenesis.

OPN was also shown to be capable of binding the CD-44 receptors, which facilitates migration and invasion of cancer cells into the blood vessels. Correlation was also demonstrated between OPN expression and the time to disease recurrence and overall survival in patients with breast cancer, gastric cancer, hepatocellular cancer, hormone-depen­dent prostate cancer, kidney cancer and endometrial cancer.

The exact mechanism responsible for OPN’s role in neoplastic transformation remains unclear and numerous research studies are conducted in this area.

Get Citation

Keywords

breast cancer, osteopontin, cancer biomarker, angiogenesis, integrin α, colorectal cancer, non-small-cell lung cancer

About this article
Title

The multidirectional role of osteopontin in cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 68, No 4 (2018)

Article type

Review paper

Pages

176-183

Published online

2019-01-16

Page views

352

Article views/downloads

475

DOI

10.5603/NJO.2018.0029

Bibliographic record

Nowotwory. Journal of Oncology 2018;68(4):176-183.

Keywords

breast cancer
osteopontin
cancer biomarker
angiogenesis
integrin α
colorectal cancer
non-small-cell lung cancer

Authors

Michał Piotr Budzik
Anna Maria Badowska-Kozakiewicz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl